NC
REGN icon

Northpointe Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Northpointe Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,672
Closed -$2.09M – 186
2017
Q3 		$2.09M Buy
+4,672
New +$2.22M 0.22% 150

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Northpointe Capital's REGN Position: Q4 2017 in Review

Northpointe Capital sold out of Regeneron Pharmaceuticals (REGN) in Q4 2017, closing a stake of 4,672 shares — an estimated $2.09M sold.

Northpointe Capital first reported a position in REGN in Q3 2017 and held it in 1 quarter. The position peaked at $2.09M in Q3 2017. 638 funds tracked by Wall St. Rank hold REGN as of Q4 2017.

  • Northpointe Capital reported no remaining Regeneron Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Northpointe Capital sold 4,672 Regeneron Pharmaceuticals shares in Q4 2017, an estimated $2.09M.
  • Northpointe Capital first reported a position in Regeneron Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Northpointe Capital's Regeneron Pharmaceuticals position peaked at $2.09M in Q3 2017.
  • 638 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2017.

Based on Northpointe Capital's 13F filing for Q4 2017, filed 23 Jan 2018.